None
Conditions
Interventions
antibody desensitisation group:High-dose IVIg
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years and no gender restriction 2. No diagnosis restriction. Meet the HSCT indications without contraindications 3. With haploidentical donor available. MFI of DSA=5000 within one month before HSCT 4. ECOG score <= 2 5. Normal blood clotting function 6. Regular follow-up, with good compliance, agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Those with severe disease and dysfunction of the heart, brain, liver, kidneys and lungs, active infection or psychological dysfunction to tolerate HSCT 3. Dependence on immuno-suppression therapy due to rheumatologic disease 4. Dependence on anti-tumor drugs due to malignancies 5. Allergic to IVIg or others 6. Second and above transplant recipients 7. Therapy history of clearance of B cells or antibodies such as RTX and proteasome inhibitor within one month before HSCT 8. Not suitable for the study after investigators' evaluation 9. Participants in other clinical studies within 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary graft failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Engraftment and engraftment time of neutrophil and platelet;Donor chimerism two weeks after HSCT;acute graft versus host disease;chronic graft versus host disease;reactivation of CMV/EBV;Post-transplantation lymphoproliferative disease;Overall survival;Disease free survival;relapse;Non-relapse mortality; | — |
Countries
China
Contacts
Public ContactYuan Li
Peking University First Hospital
Outcome results
None listed